President Biden's loss of his beloved son to brain cancer in 2015 inspired the Cancer Moonshot initiative. Dr. Harsha Rajasimha's inspiration for founding Jeeva Clinical Trials in 2019 stemmed from a similar incident: losing his precious baby to a rare disease. This ignited a fire within him to prevent such tragedies from striking other families. Driven by a proven and validated solution, Jeeva's new Enterprise platform launch aims to accelerate clinical research for life-saving therapies for cancer, rare diseases, and chronic illnesses that are more inclusive of underserved communities than ever before.
(Manassas, VA) May 13, 2024 – The clinical trial landscape is marred by persistent operational inefficiencies that have only been marginally addressed by the proliferation of technology and the shift to remote trial operations. 2024 is seeing a surge in the fight against cancer, with cancer clinical trials dominating the rest. (1) Dr. Rajasimha notes, “Despite the AI revolution, digital transformation initiatives, and the advent of remote operations, the core goals of clinical trials—to assess the safety and efficacy of treatment options—remain unchanged. They are also getting increasingly inefficient, expensive, longer, and complex due to short-sighted point solutions that address specific parts of the drug development process. We need comprehensive solutions to this nagging problem - a piecemeal approach has resulted in 90% failure rate of candidate drugs in the 'valley of death' and 30% trial terminations due to poor enrollment.” (2)
Traditional Clinical Trials Face Critical Challenges, Including:
Relevance to the Cancer Moonshot Initiative
Inspired by Pulitzer Award-winning author Siddhartha Mukherjee’s book, "The Emperor of All Maladies," which narrated a biography of our global enemy, Dr. Rajasimha acknowledges cancer's complexity, comprising over 200 subtypes. This varies based on the affected body part of origin or the cell type. To combat this, he emphasized the need for cutting-edge science and flexible, validated technology platforms that address the “whole problem” and not a piecemeal approach. The one-size-fits-all blockbuster drug model has fallen out in favor of personalized medicines, but technologies for clinical operations have not adapted to this paradigm yet. Rajasimha’s vision for JEEVA's flexible AI-driven software platform helps overcome protocol complexity for precision medicines and automate procedure assignments, appointment scheduling, and study management. His commitment aligns with the audacious goals of the Whitehouse’s Cancer Moonshot initiative, forging a powerful partnership towards excellence in Cancer clinical research and treatment.
Jeeva’s Platform Is Set to Revolutionize Global Cancer Research with Unparalleled Precision and Inclusivity
JEEVA's comprehensive eClinical platform is meticulously crafted to streamline the major components of both observational and interventional clinical studies at an enterprise scale, infusing every aspect with a relentless drive for efficiency, innovation, and inclusion without compromising quality and compliance.
Trusted by Leading Organizations: Accelerating Cancer Research with Jeeva
By centralizing data management and embracing the dynamic nature of the life science industry’s hybrid and distributed workforce, JEEVA confronts the challenges of global trial management head-on. With a steadfast commitment to improving patient recruitment and retention, coupled with a keen awareness of the financial and operational hurdles posed by regulatory standards, JEEVA stands as a ray of hope in the fight against cancer.
“If we can prevent cancer in the pre-malignant stage, it is far superior than trying to cure it when it has locally advanced or become metastatic. We have been pleased to work with JEEVA as our Electronic Data Capture (EDC) and clinical trial management system (CTMS) vendor to optimize our research data workflows under one login related to our clinical studies of pre-invasive HPV-induced lesions,” says Mihaela Plesa, BA, CCRP, Director of Clinical Research Projects, Frantz Viral Therapeutics LLC.
Aligned with the Cancer Moonshot initiative, Dr. Rajasimha's vision for JEEVA embodies purpose and determination. Scientific advances worldwide connect with global Moonshot initiatives. Collaboration with emerging markets and low- and middle-income countries (LMICs) like India is crucial for affordable treatment access.
“We needed an innovative platform for our first clinical trial with minimal financial burden and not requiring us to carry a huge IT infrastructure internally. Collaboration with Jeeva was an excellent choice for our CAR-T cell/gene therapy for leukemia and B-cell lymphoma which recently received approval from the Indian regulatory agency for a tenth of the cost compared to existing CAR-T therapies. This collaboration has been really fruitful in keeping clinical data as per regulatory requirements,” says Dr. Rahul Purwar, Founder of ImmunoACT and Associate Professor at the Indian Institute of Technology (IIT), Mumbai, India.
Collaborating Physician Investigator Dr. Hasmukh Jain from the Tata Memorial Centre presented the Indian CAR-T cell/gene therapy success story during a global collaborations session at the American Society for Cell and Gene Therapy (ASGCT) conference in Baltimore last week May 7-11, 2024. The winds of change are clearly here and now!
With an unwavering confidence in the transformative power of JEEVA's innovative platform, Rajasimha says, "With JEEVA's innovative platform, we are uniquely positioned to revolutionize cancer research, offering flexible, efficient, and compliant solutions that empower clinical researchers working towards the core objectives of the Cancer Moonshot, and propelling us towards a future where novel, safer and more effective treatment options are developed rapidly to prevent, delay, and minimize the number of deaths due to cancer."
To Learn More About Partnering with Jeeva’s Audacious Mission, Connect with Us at the Following Upcoming Events
About Jeeva Clinical Trials Inc. (“Jeeva”)
Founded by Dr. Harsha Rajasimha after his deeply personal, family, and professional experiences, Jeeva's mission to "Revolutionize Clinical Trials and Empower Outcomes" propels their innovative clinical trial management platform with AI and workflow automation under one bundled subscription. Jeeva empowers global biopharmaceutical, medical device, and nutraceutical sponsors, simplifying patient engagement and evidence generation, achieving 70% greater efficiency in research. Trusted by prestigious organizations like Frantz Viral Therapeutics and George Mason University, their technology supports diverse study designs, from traditional to fully decentralized models, across disease areas including oncology and rare diseases. With empathy and determination, Team Jeeva has developed an innovative, efficient, and compliant platform that enables sponsors to conduct clinical trials more effectively, breaking down barriers and fostering a globally inclusive and diverse participant pool. This includes facilitating remote participation. Powered by AI and automation, Jeeva is transforming the life sciences industry, one clinical trial at a time. Discover more about how Jeeva is reimagining the future of clinical trials at https://jeevatrials.com/.
References
###
Media Inquiries:
Karla Jo Helms
JOTO PR™
727-777-4619
jotopr.com